Molecular Partners Cuts Workforce by 44 Percent
Swiss biotech firm Molecular Partners is reducing its workforce by up to 44 percent to concentrate entirely on radiotherapeutic medicines. The restructuring is expected to conclude by the second quarter of 2027.
Xurve View
Insights:
Xurve View
MOLECULAR PARTNERS AG will cut up to 44% of its workforce, reducing headcount by 55 employees to focus on radiotherapeutic medicines. The Switzerland-based biotech is pivoting its pipeline following encouraging clinical data for its lead radiotherapeutic drug candidate. The restructuring impacts partnerships with pharmaceutical majors including NOVARTIS AG-REG and ABBVIE INC as development resources shift.
